

Special Issue

Hippo Signaling Pathway in Cancers

Message from the Guest Editor

The Hippo signaling pathway is known to regulate cell differentiation, cell proliferation and apoptosis. Whereas activation of the Hippo signaling pathway leads to cytoplasmic retention of the transcriptional coactivators YAP and TAZ, decreased Hippo signaling results in nuclear import of YAP/TAZ and the subsequent transcription of pro-proliferative genes. Hence, a dynamic and precise regulation of the Hippo signaling pathway is not only crucial for proper organ size control but prevents uncontrolled cell proliferation and tumor formation. This Special Issue will summarize the current knowledge on Hippo signaling in de-regulated cell proliferation and tumor formation. It will elucidate the complexity of Hippo signaling with a focus on the interplay of different signaling systems and cellular processes. Furthermore, the reader will get an update on the approaches to identify therapeutic targets within the Hippo pathway for intervention in human cancer.

Guest Editor

Dr. Joachim Kremerskothen
Universitätsklinikum Münster, Munster, Germany

Deadline for manuscript submissions

closed (15 December 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/44901

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)